BioPlus Acquisition Corp. Class A Ordinary Shares
BIOS
BIOS was delisted on the 6th of October, 2023.
67 hedge funds and large institutions have $218M invested in BioPlus Acquisition Corp. Class A Ordinary Shares in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 11 reducing their positions, and 7 closing their positions.
8% more capital invested
Capital invested by funds: $202M → $218M (+$16.3M)
9% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 11
0% more funds holding
Funds holding: 67 → 67 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Calamos Advisors
Naperville,
Illinois
|
+$10.1M |
| 2 |
CF
Cantor Fitzgerald
New York
|
+$5.81M |
| 3 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
+$2.72M |
| 4 |
LP
LMR Partners
London,
United Kingdom
|
+$2.54M |
| 5 |
SCM
Shaolin Capital Management
Miami,
Florida
|
+$1.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
-$5.97M |
| 2 |
Citigroup
New York
|
-$3.96M |
| 3 |
Parallax Volatility Advisers
San Francisco,
California
|
-$2.23M |
| 4 |
ACM
Atalaya Capital Management
New York
|
-$1.27M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$1.12M |
BIOS Hedge Fund Activity: Q4 2022 in Review
67 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) for Q4 2022, worth a combined $218M — up 8.1% from $202M a quarter earlier.
Fund positioning in BIOS was balanced in Q4 2022: 7 funds opened new positions, 7 closed out, 12 added to existing stakes and 11 trimmed.
The largest buyer was Calamos Advisors, opening a new position worth an estimated $10.1M. The largest seller was Highbridge Capital Management, cutting an estimated $5.97M.
- 67 institutional investors held BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $218M of BioPlus Acquisition Corp. Class A Ordinary Shares stock for Q4 2022, up 8.1% quarter-over-quarter.
- 7 funds opened new BioPlus Acquisition Corp. Class A Ordinary Shares positions in Q4 2022 and 7 closed out, a net change of 0 holders.
- The largest BioPlus Acquisition Corp. Class A Ordinary Shares buyer in Q4 2022 was Calamos Advisors, an estimated $10.1M added.
- The largest BioPlus Acquisition Corp. Class A Ordinary Shares seller in Q4 2022 was Highbridge Capital Management, an estimated $5.97M sold.
Based on aggregated 13F filings for Q4 2022.